PH26279A - Stabilized compositions - Google Patents

Stabilized compositions Download PDF

Info

Publication number: PH26279A
Authority: PH; Philippines
Prior art keywords: composition; drug; addition salt; pharmaceutically acceptable; acid addition
Prior art date: 1987-02-24

Application number

PH36531A

Other languages

English (en)

Inventor

Michael Harris

Gerard Hokanson

Kuchi S Murthy

Robert Reisch

Frank Waldman

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-02-24

Filing date

1988-02-19

Publication date

1992-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21785512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH26279(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-02-19 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1992-04-10 Publication of PH26279A publication Critical patent/PH26279A/en

Links

239000000203 mixture Substances 0.000 title claims description 51
239000005541 ACE inhibitor Substances 0.000 claims abstract description 13
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 13
238000007363 ring formation reaction Methods 0.000 claims abstract description 12
230000007062 hydrolysis Effects 0.000 claims abstract description 10
238000006460 hydrolysis reaction Methods 0.000 claims abstract description 10
150000001720 carbohydrates Chemical class 0.000 claims abstract description 8
239000003814 drug Substances 0.000 claims description 26
229940079593 drug Drugs 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 9
238000009472 formulation Methods 0.000 claims description 9
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 8
239000000314 lubricant Substances 0.000 claims description 8
229960001455 quinapril Drugs 0.000 claims description 8
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 8
238000002845 discoloration Methods 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
229960003042 quinapril hydrochloride Drugs 0.000 claims description 6
IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 claims description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
239000003513 alkali Substances 0.000 claims description 5
239000011230 binding agent Substances 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000008101 lactose Substances 0.000 claims description 5
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 5
239000001095 magnesium carbonate Substances 0.000 claims description 5
229910000021 magnesium carbonate Inorganic materials 0.000 claims description 5
239000000463 material Substances 0.000 claims description 5
108010061435 Enalapril Proteins 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
229960000873 enalapril Drugs 0.000 claims description 4
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
230000000087 stabilizing effect Effects 0.000 claims description 4
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 3
235000009508 confectionery Nutrition 0.000 claims description 3
239000007884 disintegrant Substances 0.000 claims description 3
229950009810 indolapril Drugs 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
239000000594 mannitol Substances 0.000 claims description 2
235000010355 mannitol Nutrition 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
-1 alkaline earth metal carbonate Chemical class 0.000 claims 2
239000003381 stabilizer Substances 0.000 abstract description 13
229910052751 metal Inorganic materials 0.000 abstract description 3
239000002184 metal Substances 0.000 abstract description 3
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000000126 substance Substances 0.000 description 7
239000003826 tablet Substances 0.000 description 7
108010010803 Gelatin Proteins 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
239000000654 additive Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000000890 drug combination Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
150000001342 alkaline earth metals Chemical class 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
239000008172 hydrogenated vegetable oil Substances 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
WFXURHIXPXVPGM-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 WFXURHIXPXVPGM-UHFFFAOYSA-N 0.000 description 1
CIWBSHSKHKDKBQ-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)-3,4-dihydroxy-2h-furan-5-one Chemical compound OCC(O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-UHFFFAOYSA-N 0.000 description 1
ZZYHCCDMBJTROG-UHFFFAOYSA-N 2-(2-benzylphenoxy)ethyl-dimethylazanium;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O.C[NH+](C)CCOC1=CC=CC=C1CC1=CC=CC=C1 ZZYHCCDMBJTROG-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
XYGSFNHCFFAJPO-UHFFFAOYSA-N Chlophedianol hydrochloride Chemical compound Cl.C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 XYGSFNHCFFAJPO-UHFFFAOYSA-N 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
239000007894 caplet Substances 0.000 description 1
229940098391 carbetapentane citrate Drugs 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940020114 chlophedianol hydrochloride Drugs 0.000 description 1
229940046978 chlorpheniramine maleate Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229960004415 codeine phosphate Drugs 0.000 description 1
229960003871 codeine sulfate Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
229960005008 doxylamine succinate Drugs 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229940029985 mineral supplement Drugs 0.000 description 1
235000020786 mineral supplement Nutrition 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
229960004708 noscapine Drugs 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229960003956 phenindamine tartrate Drugs 0.000 description 1
229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
229960002254 phenyltoloxamine citrate Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000000049 pigment Substances 0.000 description 1
BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
229940018203 pyrilamine maleate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PH36531A 1987-02-24 1988-02-19 Stabilized compositions PH26279A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/017,962 US4743450A (en)	1987-02-24	1987-02-24	Stabilized compositions

Publications (1)

Publication Number	Publication Date
PH26279A true PH26279A (en)	1992-04-10

Family

ID=21785512

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH36531A PH26279A (en)	1987-02-24	1988-02-19	Stabilized compositions

Country Status (13)

Country	Link
US (1)	US4743450A (de)
EP (1)	EP0280999B1 (de)
JP (1)	JP2619904B2 (de)
AT (1)	ATE84210T1 (de)
AU (1)	AU597471B2 (de)
CA (1)	CA1300510C (de)
DE (1)	DE3877226T2 (de)
DK (1)	DK169593B1 (de)
HK (1)	HK59496A (de)
IE (1)	IE60931B1 (de)
NZ (1)	NZ223407A (de)
PH (1)	PH26279A (de)
ZA (1)	ZA88382B (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3739690A1 (de) *	1987-11-24	1989-06-08	Hoechst Ag	Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
IL88502A (en) *	1987-12-14	1993-04-04	Squibb & Sons Inc	Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US6300361B1 (en)	1990-07-25	2001-10-09	Novartis Ag	Stabilized pharmaceutical compositions comprising acid donors
HU222489B1 (hu) *	1990-07-25	2003-07-28	Novartis Ag.	Stabilizált gyógyszerkészítmények és eljárás az előállításukra
ATE112491T1 (de)	1990-09-13	1994-10-15	Akzo Nobel Nv	Stabilisierte feste chemische zusammensetzungen.
US5292520A (en) *	1990-09-13	1994-03-08	Akzo N.V.	Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US5238935A (en) *	1991-05-20	1993-08-24	Schering Corporation	N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A: cholesterol acyl transferase
US5124337A (en) *	1991-05-20	1992-06-23	Schering Corporation	N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
FR2665834B1 (fr) *	1991-07-24	2001-02-23	Sandoz Sa	Composition pharmaceutique stabilisee par un donneur d'acide chlorhydrique, et sa preparation.
TW284688B (de) *	1991-11-20	1996-09-01	Takeda Pharm Industry Co Ltd
SI9111842A (sl) *	1991-11-25	1998-04-30	Krka	Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba
TW483763B (en) *	1994-09-02	2002-04-21	Astra Ab	Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5573780A (en) *	1995-08-04	1996-11-12	Apotex Usa Inc.	Stable solid formulation of enalapril salt and process for preparation thereof
US6296871B1 (en)	1998-04-12	2001-10-02	Ranbaxy Laboratories Limited	Stable solid pharmaceutical compositions containing enalapril maleate
US6153223A (en) *	1998-06-05	2000-11-28	Watson Pharmaceuticals, Inc.	Stabilized pharmaceutical compositions
EP1083931B1 (de)	1998-06-05	2005-05-11	Warner-Lambert Company LLC	Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
US20030027837A1 (en) *	1998-12-08	2003-02-06	Sherman Bernard Charles	Pharmaceutical compositions comprising quinapril magnesium
NZ333206A (en) *	1998-12-08	2000-07-28	Bernard Charles Sherman	Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
US6637359B1 (en) *	1998-12-15	2003-10-28	Maritrans Inc.	System and method for internally fitting a new inner hull to an existing outer hull to form a rebuilt double hull vessel
US6060461A (en) *	1999-02-08	2000-05-09	Drake; James Franklin	Topically applied clotting material
MY121470A (en) *	1999-05-03	2006-01-28	Ranbaxy Lab Ltd	Stable solid pharmaceutical compositions containing enalapril maleate
SE9903028D0 (sv)	1999-08-27	1999-08-27	Astra Ab	New use
HUP0203326A3 (en) *	1999-08-30	2003-04-28	Sanofi Aventis Deutschland	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6555551B1 (en)	1999-08-31	2003-04-29	Mutual Pharmaceutical Co., Inc.	Stable formulations of ACE inhibitors, and methods for preparation thereof
US20030225124A1 (en) *	1999-08-31	2003-12-04	Spiridon Spireas	Stable formulations of ACE inhibitors, and methods for preparation thereof
US6764694B1 (en) *	1999-08-31	2004-07-20	Mutual Pharmaceutical Co., Inc.	Stable formulations of ACE inhibitors, and methods for preparation thereof
US20040157911A1 (en) *	1999-08-31	2004-08-12	Spiridon Spireas	Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
CA2303481A1 (en) *	2000-04-05	2001-10-05	Bernard Charles Sherman	Pharmaceutical compositions comprising moexipril magnesium
US6333332B1 (en) *	2000-08-25	2001-12-25	Impax Laboratories, Inc.	Stabilized pharmaceutical compositions containing bupropion hydrochloride
TWI232102B (en)	2001-07-17	2005-05-11	Shionogi & Co	A pharmaceutical formulation for injection
US20040170689A1 (en) *	2001-11-09	2004-09-02	Odink Debra Alida	Stabilized formulations comprising hydrolytically unstable compositions
EA007981B1 (ru) *	2002-01-15	2007-02-27	Актавис Груп Хф.	Фармацевтический состав, содержащий хинаприл или фармацевтически приемлемую его соль
EP1467717A1 (de) *	2002-01-15	2004-10-20	Ranbaxy Laboratories Limited	Stabile pharmazeutische zusammensetzungen mit ace-inhibitor(en)
US20030157165A1 (en) *	2002-02-01	2003-08-21	Sherman Bernard Charles	Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US20030215526A1 (en) *	2002-03-08	2003-11-20	Scott Stofik	Stable formulations of angiotensin converting enzyme (ACE) inhibitors
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2530788C (en) *	2003-06-26	2010-02-09	Teva Pharmaceutical Industries Ltd	Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
US6869963B2 (en) *	2003-07-11	2005-03-22	Sandoz Ag	Stable pharmaceutical compositions containing an ACE inhibitor
WO2005027881A2 (en) *	2003-09-23	2005-03-31	Texcontor Etablissement	Stable quinapril compositions
US20050181055A1 (en) *	2003-10-08	2005-08-18	Mathur Rajeev S.	Pharmaceutical compositions of quinapril
AU2003300692A1 (en) *	2003-10-30	2005-05-19	Lupin Ltd.	Stable formulations of ace inhibitors and methods for preparation thereof
GB2411355B (en)	2004-02-27	2006-02-22	Niche Generics Ltd	Pharmaceutical composition
WO2005067887A2 (en) *	2004-03-24	2005-07-28	Actavis Group	Formulations of ramipril
PT1729739T (pt) *	2004-03-29	2016-12-01	Servier Lab	Processo para a preparação de uma composição farmacêutica sólida
SI21800A (sl)	2004-05-14	2005-12-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Nov postopek sinteze perindoprila
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008024592A (ja) *	2005-01-28	2008-02-07	Taisho Pharmaceut Co Ltd	シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
GR1006875B (el) *	2005-06-30	2010-07-12	"Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε.,	Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
GB0518129D0 (en) *	2005-09-06	2005-10-12	Arrow Int Ltd	Ramipril formulation
GB2431579A (en) *	2005-10-28	2007-05-02	Arrow Int Ltd	Ramipril formulations
US20070098782A1 (en) *	2005-10-28	2007-05-03	Selamine Limited	Ramipril Formulation
RS53324B (sr)	2005-11-17	2014-10-31	Silverstone Pharma Est.	Stabilna formulacija amorfnih soli perindoprila, postupak za njihovu pripremu, naročito industrijsku pripremu, i njihova upotreba u terapiji hipertenzije
EP1815857A1 (de)	2006-02-02	2007-08-08	LEK Pharmaceuticals D.D.	Pharmazeutische Zusammensetzung enthaltend Perindopril
US20070232680A1 (en) *	2006-04-04	2007-10-04	Vijayabhaskar Bolugoddu	Preparation of ramipril and stable pharmaceutical compositions
US7943655B2 (en) *	2006-04-05	2011-05-17	Universitat Zurich	Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
AU2007264414A1 (en) *	2006-06-30	2008-01-03	Alphapharm Pty Ltd	A stabilised composition comprising ACE inhibitors
GB0624084D0 (en) *	2006-12-01	2007-01-10	Selamine Ltd	Ramipril amino acid salts
GB0624090D0 (en) *	2006-12-01	2007-01-10	Selamine Ltd	Ramipril amine salts
GB0624087D0 (en) *	2006-12-01	2007-01-10	Selamine Ltd	Ramipril combination salt
AU2008290582B2 (en) *	2007-08-17	2014-08-14	Boehringer Ingelheim International Gmbh	Purin derivatives for use in the treatment of fab-related diseases
JP2009084242A (ja) *	2007-10-02	2009-04-23	Nichi-Iko Pharmaceutical Co Ltd	安定性に優れた塩酸テモカプリル錠剤
JP5113476B2 (ja) *	2007-10-09	2013-01-09	沢井製薬株式会社	保存安定性に優れた塩酸テモカプリルの錠剤
CN101854932A (zh) *	2007-11-07	2010-10-06	詹森药业有限公司	包含血管紧张素转化酶抑制剂和加压素受体拮抗剂的组合疗法
WO2009113081A1 (en) *	2008-03-10	2009-09-17	Lupin Limited	Tris (hydroxymethyl ) amino methane salt of quinapril and ramipril
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX370599B (es) *	2008-08-15	2019-12-18	Boehringer Ingelheim Int	Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TR200906322A2 (tr)	2009-08-17	2011-07-21	Bi̇lgi̇ç Mahmut	Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
BR112012003592B8 (pt)	2009-08-19	2021-05-25	Eisai R&D Man Co Ltd	composição farmacêutica contendo derivado de quinolina
ES2364011B1 (es)	2009-11-20	2013-01-24	Gp Pharm, S.A.	Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
EP2585051B2 (de)	2010-06-23	2020-04-08	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmazeutische orale dosierformen mit lercandipin und enalapril und ihren pharmazeutisch akzeptablen salzen
NZ603319A (en)	2010-06-24	2015-04-24	Boehringer Ingelheim Int	Diabetes therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012085249A2 (en)	2010-12-24	2012-06-28	Krka, D.D., Novo Mesto	Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
WO2012166899A2 (en)	2011-06-03	2012-12-06	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2841552C (en)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (de)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US8568747B1 (en)	2012-10-05	2013-10-29	Silvergate Pharmaceuticals, Inc.	Enalapril compositions
PL227900B1 (pl)	2012-11-15	2018-01-31	Adamed Spolka Z Ograniczona Odpowiedzialnoscia	Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
US9937153B2 (en)	2013-08-30	2018-04-10	Merck Sharp & Dohme Ltd.	Oral pharmaceutical formulation of omarigliptin
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
HUE041705T2 (hu)	2014-07-31	2019-05-28	Pharmathen Sa	Enalaprilt tartalmazó, szájban diszpergálódó film készítmény magas vérnyomás kezelésére gyermek populációban
CA2957005C (en)	2014-08-28	2021-10-12	Eisai R&D Management Co., Ltd.	High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en)	2015-02-25	2017-09-28	Eisai R&D Man Co Ltd	Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en)	2015-03-04	2016-09-09	Merck Sharp & Dohme Corp.	Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt)	2015-06-16	2023-12-12	Eisai R&D Management Co., Ltd	Agente anti-câncer
JP6553726B2 (ja)	2015-08-20	2019-07-31	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
US9463183B1 (en)	2015-10-30	2016-10-11	Silvergate Pharmaceuticals, Inc.	Lisinopril formulations
US20180325813A1 (en)	2015-11-07	2018-11-15	Ftf Pharma Private Limited	Oral solution of ace inhibitors
US9669008B1 (en)	2016-03-18	2017-06-06	Silvergate Pharmaceuticals, Inc.	Enalapril formulations
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
US12303505B2 (en)	2017-02-08	2025-05-20	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
BR112019023064A2 (pt)	2017-05-16	2020-06-09	Eisai R&D Man Co Ltd	tratamento de carcinoma hepatocelular

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1422176A (en) *	1973-05-05	1976-01-21	Beecham Group Ltd	Pharmaceutical tablets
US4255413A (en) *	1979-10-01	1981-03-10	Smithkline Corporation	Gelatin capsule dosage unit containing triamterene
ATE25244T1 (de) *	1981-12-29	1987-02-15	Hoechst Ag	Neue derivate bicyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung.
US4584299A (en) *	1984-05-21	1986-04-22	Warner-Lambert Company	Method of treating heart failure and medicaments therefor
US4656188A (en) *	1985-10-09	1987-04-07	Merck & Co., Inc.	Ace inhibitors in macular degeneration
JPH06104680B2 (ja) *	1985-11-13	1994-12-21	株式会社大塚製薬工場	プロリン誘導体
DE3610391A1 (de) *	1986-03-27	1987-10-08	Hoechst Ag	Verbindungen mit nootroper wirkung, diese enthaltende mittel und deren verwendung bei der behandlung und prophylaxe cognitiver dysfunktionen

1987
- 1987-02-24 US US07/017,962 patent/US4743450A/en not_active Expired - Lifetime
1988
- 1988-01-20 CA CA000556913A patent/CA1300510C/en not_active Expired - Lifetime
- 1988-01-20 ZA ZA88382A patent/ZA88382B/xx unknown
- 1988-01-20 IE IE14288A patent/IE60931B1/en not_active IP Right Cessation
- 1988-02-04 AU AU11305/88A patent/AU597471B2/en not_active Expired
- 1988-02-04 NZ NZ223407A patent/NZ223407A/xx unknown
- 1988-02-19 PH PH36531A patent/PH26279A/en unknown
- 1988-02-23 EP EP88102643A patent/EP0280999B1/de not_active Expired - Lifetime
- 1988-02-23 AT AT88102643T patent/ATE84210T1/de not_active IP Right Cessation
- 1988-02-23 DK DK094088A patent/DK169593B1/da not_active IP Right Cessation
- 1988-02-23 DE DE8888102643T patent/DE3877226T2/de not_active Expired - Lifetime
- 1988-02-23 JP JP63038776A patent/JP2619904B2/ja not_active Expired - Lifetime
1996
- 1996-04-03 HK HK59496A patent/HK59496A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU1130588A (en)	1988-08-25
DK94088A (da)	1988-08-25
ZA88382B (en)	1989-09-27
IE60931B1 (en)	1994-09-07
DE3877226D1 (de)	1993-02-18
EP0280999A3 (en)	1988-11-17
JP2619904B2 (ja)	1997-06-11
AU597471B2 (en)	1990-05-31
IE880142L (en)	1988-08-24
JPS63225322A (ja)	1988-09-20
DK94088D0 (da)	1988-02-23
CA1300510C (en)	1992-05-12
HK59496A (en)	1996-04-12
DE3877226T2 (de)	1993-04-29
ATE84210T1 (de)	1993-01-15
EP0280999A2 (de)	1988-09-07
DK169593B1 (da)	1994-12-19
US4743450A (en)	1988-05-10
EP0280999B1 (de)	1993-01-07
NZ223407A (en)	1989-08-29

Publication	Publication Date	Title
US4743450A (en)	1988-05-10	Stabilized compositions
EP0264887B1 (de)	1991-09-11	Gegen Oxydierung und Verfärbung stabilisierte Arzneimittelzubereitungen
EP0264888B1 (de)	1991-08-07	Stabilisierte Arzneimittelzubereitungen
EP1083931B1 (de)	2005-05-11	Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
NO323229B1 (no)	2007-02-05	Flytende eller faste farmasoytiske preparater inneholdende cilansetron stabilisert mot racemisering, anvendelse av sure tilsetningsstoffer til stabiliseringen og fremgangsmate for fremstilling av slike faste preparater
CA2286904A1 (en)	1998-10-22	Pharmaceutical tablet of amiodarone salt
EP1178793B1 (de)	2005-11-30	Enalaprilmaleat enthaltende, stabile, feste arzneimittel
MXPA00011299A (en)	2001-07-31	Stabilization of compositions containing ace inhibitors using magnesium oxide